ABSTRACT
Vasoactive intestinal polypeptide secreting islet cell tumors (VIPomas) are neuroendocrine tumors that secrete excessive amounts of vasoactive intestinal polypeptide (VIP) that cause distinct syndromes characterized by large-volume diarrhea, hypokalemia, and dehydration. The annual incidence of these tumors is estimated to be about one per 10,000,000 individuals in the general population. We report a successful treatment of VIPoma with hepatic chemoembolization of a metastatic hepatic lesion evidenced by a reduction of VIP levels and resolutions of symptoms in a patient with pancreatic VIPoma unresponsive to increased doses of an octreotide analog.
Free PMC Article
Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma
Riferimento:
Yale J Biol Med. 2010 Mar;83(1):27-33.
Autori:
Shaib W1, Mitchell K, Saif MW.
Fonte:
Yale J Biol Med. 2010 Mar;83(1):27-33.
Anno:
2010
Azione:
Trattamento di tumori delle cellule insulari secernenti polipeptide intestinale vasoattivo (VIPomi) con chemioembolizzazione di una lesione epatica metastatica rispondente ad un aumento della dose di octreotide.
Target:
Octreotide/tumori delle cellule insulari pancreatiche.
Sostanze: